Mod GRF 1-29 vs CJC-1295 No DAC: Sourcing and Verification
| Feature | Mod GRF 1-29 | CJC-1295 No DAC | CJC-1295 With DAC | Professional Assessment ||—|—|—|—|| Amino Acid Sequence | 29 AA, tetrasubstituted GRF(1-29)NH2 | 29 AA, tetrasubstituted GRF(1-29)NH2 | 29 AA + DAC conjugate | Mod GRF 1-29 and CJC-1295 no DAC ar
This comparison does not assign a generated winner or score.
- | Feature | Mod GRF 1-29 | CJC-1295 No DAC | CJC-1295 With DAC | Professional Assessment ||—|—|—|—|| Amino Acid Sequence | 29 AA, tetrasubstituted GRF(1-29)NH2 | 29 AA, tetrasubstituted GRF(1-29)NH2 | 29 AA + DAC conjugate | Mod GRF 1-29 and CJC-1295 no DAC are identical; with DAC is a distinct compound || Molecular Weight | 3367.9 Da | 3367.9 Da | ~5000 Da (varies by DAC linker) | Identical mass confirms identity; DAC adds significant mass || Plasma Half-Life | ~30 minutes | ~30 minutes | 6–8 days | No-DAC forms require multiple daily doses; DAC allows weekly dosing || Dosing Protocol | 100–200 mcg, 2–3x daily | 100–200 mcg, 2–3x daily | 1–2 mg, weekly | Pulsatile vs sustained release dictates administration frequency || GH Secretion Pattern | Sharp peaks, returns to baseline in 90–120 min | Sharp peaks, returns to baseline in 90–120 min | Sustained elevation, blunted peaks | Only no-DAC forms replicate physiological pulsatility || Reconstitution Stability | 28 days at 2–8°C in acidic
- Verifying peptide identity requires mass spectrometry and HPLC analysis. Visual inspection and vendor labeling are insufficient. A certificate of analysis (CoA) should list molecular weight within ±2 Da of the theoretical mass (3367.9 Da for Mod GRF 1-29 and CJC-1295 no DAC), purity ≥98% by HPLC, and peptide content by weight (typically 1–5 mg per vial). If the CoA lists molecular weight above 4500 Da, the peptide contains DAC regardless of labeling. If no CoA is provided, the peptide should not be used in research. Synthesis variability, incomplete deprotection, and oxidation byproducts are common quality control failures in peptide manufacturing.